AU2079901A - Thrombopoietin mimetics - Google Patents

Thrombopoietin mimetics

Info

Publication number
AU2079901A
AU2079901A AU20799/01A AU2079901A AU2079901A AU 2079901 A AU2079901 A AU 2079901A AU 20799/01 A AU20799/01 A AU 20799/01A AU 2079901 A AU2079901 A AU 2079901A AU 2079901 A AU2079901 A AU 2079901A
Authority
AU
Australia
Prior art keywords
mammal
invented
thrombopoietin mimetics
mimetics
thrombopoietin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU20799/01A
Other languages
English (en)
Inventor
Kevin J. Duffy
Juan I. Luengo
Alan T. Price
Lihua Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2079901A publication Critical patent/AU2079901A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU20799/01A 1999-12-06 2000-12-06 Thrombopoietin mimetics Abandoned AU2079901A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16913099P 1999-12-06 1999-12-06
US60169130 1999-12-06
PCT/US2000/033432 WO2001039773A1 (en) 1999-12-06 2000-12-06 Thrombopoietin mimetics

Publications (1)

Publication Number Publication Date
AU2079901A true AU2079901A (en) 2001-06-12

Family

ID=22614367

Family Applications (1)

Application Number Title Priority Date Filing Date
AU20799/01A Abandoned AU2079901A (en) 1999-12-06 2000-12-06 Thrombopoietin mimetics

Country Status (7)

Country Link
EP (1) EP1244446B1 (https=)
JP (1) JP2003515560A (https=)
AT (1) ATE344031T1 (https=)
AU (1) AU2079901A (https=)
DE (1) DE60031714T2 (https=)
ES (1) ES2275567T3 (https=)
WO (1) WO2001039773A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2495184A1 (en) 2002-08-14 2004-02-26 Nissan Chemical Industries, Ltd. Thrombopoietin receptor activators and process for their production
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
AU2003302238A1 (en) 2002-12-03 2004-06-23 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
SI1569907T1 (sl) * 2002-12-13 2016-06-30 Ym Biosciences Australia Pty Ltd Na nikotinamidu osnovani kinazni inhibitorji
EP1581527A4 (en) * 2002-12-13 2006-11-22 Smithkline Beecham Corp MIMETICS OF THROMBOPOIETINE
TW200418791A (en) * 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
US7470807B2 (en) 2003-08-14 2008-12-30 Asahi Kasei Pharma Corporation Substituted arylalkanoic acid derivatives and use thereof
US8729117B2 (en) 2004-06-02 2014-05-20 Pharmacyclics, Inc. Factor VIIa inhibitor
US8552031B2 (en) 2004-12-08 2013-10-08 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
AU2005314788B2 (en) 2004-12-14 2011-09-22 Nissan Chemical Industries, Ltd. Amide compound and thrombopoietin receptor activator
ATE478863T1 (de) 2005-07-14 2010-09-15 Irm Llc Heterotetracyclische verbindungen als tpo- mimetica
NZ563202A (en) 2005-07-15 2011-02-25 Nissan Chemical Ind Ltd Thiophene compounds and thrombopoietin receptor activators
KR101290484B1 (ko) 2005-07-20 2013-07-26 닛산 가가쿠 고교 가부시키 가이샤 피라졸 화합물 및 트롬보포이에틴 수용체 활성화제
US7816542B2 (en) * 2005-08-15 2010-10-19 Irm Llc Compounds and compositions as TPO mimetics
EP1947101A4 (en) 2005-11-07 2009-09-16 Nissan Chemical Ind Ltd HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
EP2025671A4 (en) 2006-06-07 2011-04-06 Nissan Chemical Ind Ltd NITROGENIC HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
PT2054405E (pt) 2006-07-11 2013-12-24 Dae Woong Pharma Novos derivados de biaril benzoimidazol e composição farmacêutica que compreende os mesmos
NZ580662A (en) 2007-04-30 2012-01-12 Abbott Lab Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme used in manufacture of medicament for treatment of diabetes or lipid associated disorders
CN101481352A (zh) 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CN101921232A (zh) 2009-06-11 2010-12-22 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
WO2012102937A2 (en) 2011-01-25 2012-08-02 Irm Llc Compounds that expand hematopoietic stem cells
CA2858069C (en) 2011-12-08 2020-02-11 Novartis Ag Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
PT2807165T (pt) 2012-01-27 2019-07-12 Univ Montreal Derivados de pirimido[4,5-b]indole e sua utilização na expansão de células estaminais hematopoiéticas
CA2946446C (en) 2014-04-22 2020-11-03 Universite De Montreal Pyrido-pyrrolo-pyrimidine and pyrido-indole compounds, pharmaceutical compositions containing same and their use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells
CA2966150A1 (en) 2014-10-31 2016-05-06 Nissan Chemical Industries, Ltd. Ligand-binding fiber and cell culture substrate using said fiber

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE193350C (https=) *
US851444A (en) * 1905-11-13 1907-04-23 Agfa Ag Amido-oxy-sulfonic acid of phenylnaphthimidazol and process of making same.
US4435417A (en) * 1981-02-20 1984-03-06 Gruppo Lepetit S.P.A. Antiinflammatory 3H-naphtho[1,2-d]imidazoles
DE4126612A1 (de) * 1990-08-14 1992-02-20 Ciba Geigy Ag Reaktivfarbstoffe, deren herstellung und verwendung
IE70217B1 (en) * 1990-08-15 1996-10-30 British Bio Technology Benzimidazole derivatives process for their preparation and application

Also Published As

Publication number Publication date
JP2003515560A (ja) 2003-05-07
DE60031714T2 (de) 2007-09-06
DE60031714D1 (de) 2006-12-14
EP1244446A1 (en) 2002-10-02
ES2275567T3 (es) 2007-06-16
ATE344031T1 (de) 2006-11-15
EP1244446A4 (en) 2003-01-08
WO2001039773A1 (en) 2001-06-07
EP1244446B1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
AU2079901A (en) Thrombopoietin mimetics
EP1223944A4 (en) THROMBOPOIETINMIMETIKA
EP1213965A4 (en) Thrombopoietin mimetics
HK1043472A1 (zh) 血小板减少症拟态
WO2002049413A3 (en) Thrombopoietin mimetics
MY136707A (en) Thrombopoietin mimetics
WO2004054515A3 (en) Thrombopoietin mimetics
EP1133291A4 (en) THROMCOCYTOPENIA TREATMENTS
AU2002328972A1 (en) Piperidine derivatives as antibacterial agents
AU2207000A (en) Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
AU6825300A (en) Compounds
AU3831301A (en) Method for treating ocular pain
AU2119200A (en) Medicament
AP2001002291A0 (en) Novel method of treatment.
ZA200108215B (en) Compositions and methods for treatment of staphylococcal infection.
AU3227700A (en) Skin sanitizing compositions
CY1108221T1 (el) Μεθοδος για την αναπαραγωγη πλευρομουτιλινων
AU4651700A (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
AUPQ866500A0 (en) Therapeutic compounds and methods
IL131478A0 (en) Methods for treatment of scar tissue
WO2000042987A8 (en) Targeted vesicular constructs for cytoprotection and treatment of h. pylori infections
AU5639700A (en) Targeted anticalcification treatment
AU1618901A (en) Treatment of rosacea
AU4193800A (en) Use of tagatose to enhance key blood factors
AU2837500A (en) Pesticidal use of a parasitic flagellate for eliminating or suppressing harmful algae blooms

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase